Kevan Shokat received a BA in Chemistry from Reed College in 1986 and a PhD in organic chemistry from the University of California, Berkeley. He carried out postdoctoral work in cellular immunology at Stanford University. Dr. Shokat’s research group is focused on the discovery of new small molecule tools and drug candidates targeting regulatory proteins such as protein/lipid kinases and GTPases, as well as RNA helicases. His laboratory uses the tools of synthetic organic chemistry, protein engineering, structural biology, biochemistry and cell biology. He was inducted into the National Academy of Sciences (2010), the National Academy of Medicine (2011), and the American Academy of Arts and Sciences (2011). He has commercialized discoveries from his laboratory through co-founding several biotechnology companies including Intellikine, Araxes, Wellspring Biosciences, Kura Oncology, eFFECTOR Therapeutics, Mitokinin, Revolution Medicines, Erasca and Kumquat Biosciences.